Management of TRK Fusion Cancer: Evaluating Targeted Therapies - Participating Faculty

PARTICIPATING FACULTY

Marcia S. Brose, MD, PhD

Director of Cancer Services

Sidney Kimmel Cancer Center

Thomas Jefferson University Hospitals

Philadelphia, PA

Josh J. Carlson, PhD, MPH

Associate Professor

CHOICE Institute, School of Pharmacy

University of Washington

Seattle, WA

Noah Federman, MD

Clinical Professor

Director, Pediatric Bone and Soft Tissue

Sarcoma Program

David Geffen School of Medicine

University of California, Los Angeles

Los Angeles, CA

Antoine Italiano, MD, PhD

Professor

Early Phase Trials and Sarcoma Units

Institut Bergonié

Bordeaux, France

Shivaani Kummar, MD, FACP

DeArmond Endowed Chair of Cancer Research

Professor and Head, Division of Hematology and

Medical Oncology

Codirector, Center for Experimental Therapeutics

Knight Cancer Institute

Oregon Health and Science University

Portland, OR

Ulrik Lassen, MD, PhD

Professor of Clinical Oncology

Department of Oncology

Rigshospitalet

Copenhagen, Denmark

Sean D. Sullivan, PhD, MSc, RPh

Dean and Professor of Pharmacy

School of Pharmacy

Hutchinson Institute for Cancer

Outcomes Research

Fred Hutchinson Cancer Research Center

University of Washington

Seattle, WA

FACULTY DISCLOSURES

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Marcia S. Brose, MD, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

AstraZeneca, Bayer, Eli Lilly and Company,

Genentech, Loxo Oncology

HONORARIA

Clinical Care Options, Medscape,

OncLive^®, PeerView

INSTITUTIONAL CONFLICTS OF INTEREST

Research support to the University of

Pennsylvania School of Pharmacy from

Bayer, Blueprint Medicines, Eisai, Eli Lilly and

Company, Genentech, Loxo Oncology, Novartis

Josh J. Carlson, PhD, MPH

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer

HONORARIA

Adaptive Biotechnologies

Noah Federman, MD

CONSULTANTIES OR PAID ADVISORY BOARDS

Bayer, Loxo Oncology

GRANTS RECEIVED

Research is supported by NIH National Center

for Advancing Translational Science (NCATS)

UCLA Clinical & Translational Science Institute

(CTSI) Grant Number UL1TR001881

LECTURE FEES FOR SPEAKING AT THE

INVITATION OF A COMMERCIAL SPONSOR

Bayer

ROYALTIES

NanoValent Pharmaceuticals, Inc

STOCK OWNERSHIP

Stock held in for-profit health care companies

bluebird bio, Inc, Genmab, Reata Pharmaceuticals

Antoine Italiano, MD, PhD

GRANTS RECEIVED

AstraZeneca, Bayer, Merck, Merck Sharp &

Dohme, PharmaMar, Roche

HONORARIA

Bayer, Daiichi Sankyo, Epizyme, Ipsen,

Roche, SpringWorks Therapeutics

Shivaani Kummar, MD, FACP

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer, Boehringer Ingelheim, EcoR1 Capital,

Genome & Company, Gilead, Harbour Biomed,

Seagen, SpringWorks Therapeutics, Mirati

Therapeutics, Mundipharma

STOCK OWNERSHIP

Cofounder and equity holder for PathomIQ

OTHER

Editor-in-chief of Current Problems in Cancer

(Elsevier); spouse is a scientific adviser

for Cadila Pharmaceuticals Ltd and founder

of Arxeon, Inc

Ulrik Lassen, MD, PhD

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer, Novartis, Pfizer

GRANTS RECEIVED

Bristol Myers Squibb, GlaxoSmithKline,

Pfizer, Roche

Sean D. Sullivan, PhD, MSc, RPh

CONSULTANCIES OR PAID ADVISORY BOARDS

Bayer

Signed disclosures are on file at the office of The American Journal of Managed Care^®, Cranbury, New Jersey.

Download PDF